English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Infants With Symptomatic SMA Reach Milestones With Gene Therapy
Gene replacement therapy with onasemnogene abeparvovec (Zolgensma) enabled symptomatic infants with spinal muscular atrophy type 1 (SMA1) to achieve at least one episode of independent sitting, the open-label phase III STR1VE-EU trial showed.
Fourteen of 32 patients met the primary endpoint of achieving independent sitting for at least 10 seconds by age 18 months, reported Eugenio Mercuri, MD, PhD, of Catholic University in Rome, and colleagues. In contrast, none of 23 infants in a natural history cohort met that goal (P<0.0001), they wrote in Lancet Neurology.
Nearly all SMA1 patients who received onasemnogene abeparvovec — 31 of 32 infants in the intention-to-treat population — survived free from permanent ventilation at 14 months, a secondary endpoint. In the natural history cohort, only six infants achieved that outcome (P<0.0001).
BookmarkRelated Content
-
A Caregiver’s Guide to ZolgensmaIndication ZOLGENSMA® (onasemnogene abe...
-
Gene Replacement Therapy With Onasemnogene Abeparvovec in Children With Spinal Muscular Atrophy Aged 24 Months or Yo...Given the novelty of gene replacement th...
-
Coverage of Genetic Therapies for Spinal Muscular Atrophy Across Fee-for-Service Medicaid ProgramsBackground: Genetic therapies are a prom...
-
Spinal Muscular Atrophy 2019: SMA Pathophysiology, Diagnosis and Clinical Presentationshttps://www.youtube.com/watch?v=cUuWue8M...
-
Spinal Muscular Atrophy Fact SheetWhat is spinal muscular atrophy?Spinal m...
-
Expert Recommendations and Clinical Considerations in the Use of Onasemnogene Abeparvovec Gene Therapy for Spinal Mu...Spinal muscular atrophy (SMA) is an auto...
-
Patient of the Month: GiannaAfter noticing that her daughter was una...
Powered by
In partnership with
